Mount Tam Biotechnologies, Inc., and Isomerase Therapeutics Announce Expansion of Their Collaboration to Discover and Develop Novel Rapalogs

NOVATO, Calif., Jan. 09, 2017 -- Mount Tam Biotechnologies, Inc. ("Mount Tam") (OTC PINK:MNTM) is pleased to announce that Mount Tam and Cambridge, UK-based Isomerase Therapeutics Ltd (“Isomerase”) have agreed to expand their research collaboration for the discovery and development of novel rapalogs in 2017.  As part of this research collaboration, Mount Tam will work to characterize and advance discovery programs for a range of novel and proprietary rapalogs that have been developed through Isomerase’s proprietary approach to improving microbial natural products via their unique biosynthetic medicinal chemistry platform.

The ultimate goal of this collaboration is to discover and develop differentiated mTOR modulators that can improve upon currently marketed rapalogs and further strengthen Mount Tam’s current portfolio of proprietary compounds.  Richard Marshak, Mount Tam’s CEO, said, “We are excited by the opportunity to work with these novel rapalogs given the great potential for mTOR modulators to address a wide range of serious unmet medical needs across a range of therapeutic areas where satisfactory treatments are lacking.  It is also rewarding to advance our collaboration with the team at Isomerase, one of the world’s leaders in advancing microbial natural products.”

About Mount Tam Biotechnologies, Inc.

Mount Tam Biotechnologies was established to develop, optimize and bring to market novel pharmaceutical products to improve the health and well-being of patients suffering from a range of serious disease states where there is significant unmet need. Our most advanced compound is being developed to treat systemic lupus erythematosus (SLE). 

Mount Tam has partnered with the world-renowned Buck Institute for Research on Aging through a worldwide exclusive licensing and collaboration agreement. The assets are highly target-specific polyketides--a class of compounds with a successful track record with the FDA drug approval process. The assets are supported by intellectual property consisting of over 45 worldwide issued patents and patent applications, including composition of matter, manufacturing and therapeutic area applications.

Mount Tam is advancing its lead asset, TAM-01, toward an Investigational New Drug (IND) application with the FDA and has already completed non-GLP pre-clinical development. The lead indication for TAM-01 is expected to be the treatment of SLE.  Mount Tam is also advancing follow-on compounds through the discovery process and is looking at a broad range of disease areas where novel mTOR inhibitors have been shown to have the potential to address unmet need.

For more information visit www.MountTamBiotech.com

Forward-Looking Statements:

The information disclosed in this press release is made as of the date hereof and reflects Mount Tam’s most current assessment of its historical position and financial performance. Actual results may differ from those contained herein due to factors outside of the control of Mount Tam. Additionally, this press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections.

These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors Mount Tam identifies from time to time in its filings with the SEC. Forward-looking statements are identified by wording such as "scheduled (future sense)", "intend(s)", "plan(s)", "expect(s)", "believe(s)", "will", "estimate(s)", "anticipate(s)", "expect(s)", "may", "would", "could" or "should" or, in each case, the negative thereof, other variations thereon, or comparable terminology that implies anticipated future performance, timing of an IND application, or the results of any such application.  Although Mount Tam believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Mount Tam disclaims any intention or obligation to update the forward-looking statements for subsequent events.

Company Contact:
Jim Stapleton
Chief Financial Officer
[email protected]
Phone: 425-214-4079